Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese And/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials

Overview

Journal J Clin Res Pediatr Endocrinol

Specialties Endocrinology
Pediatrics

Date 2024 Jun 3

PMID 38828884

Authors

Min Dai

Senjie Dai

Lihu Gu

Zhiyi Xiang

Anyi Xu

Siyu Lu

Yang Yang

Cong Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this meta-analysis was to investigate the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on blood glucose and weight in adolescents with overweight/obesity and/or type 2 diabetes mellitus (T2DM) aged <18 years.

Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.

Results: Fourteen RCTs were included in the meta-analysis with a total of 1,262 participants. Results revealed that the GLP-1RAs group had a more significant reduction in glycosylated hemoglobin A1c (HbA1c; risk difference (RD)=-0.34%, p<0.001) than the control group. However, there was no difference in fasting plasma glucose [fasting plasma glucose (FPG); RD=-2.07 mg/dL, p=0.065] between the two groups. Nonetheless, the experimental group that received exenatide showed no significant reduction in HbA1c (p=0.253) and FPG (p=0.611) between the two groups. The GLP-1RAs group had a more significant decline in body weight (RD=-4.28 kg, p=0.002) and body mass index (BMI) (RD=-1.63 kg/m, p=0.002) compared to the control group. The experimental group was given liraglutide (RD=-2.31 kg, p=0.038) or exenatide (RD=-2.70 kg, p<0.001). Compared to the control group, the experimental group had a more significant drop in body weight than the control group. However, for the experimental group that received liraglutide, the BMI had a no significant reduction between the two groups (RD=-0.81 kg/m, p=0.260). For the experimental group using exenatide, BMI declined more significantly in the intervention group than in the control group (RD=-1.14 kg/m, p<0.001).

Conclusion: This study showed that GLP-1RAs reduced HbA1c, FPG, and weight loss in overweight/obese and/or T2DM adolescents. Liraglutide was better than exenatide in terms of glucose reduction. Nevertheless, in terms of weight control, exenatide was more effective than liraglutide.

Citing Articles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.

Gaggini M, Sabatino L, Suman A, Chatzianagnostou K, Vassalle C Cells. 2025; 14(5).

PMID: 40072115 PMC: 11898734. DOI: 10.3390/cells14050387.

Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.

Wu Y, Yang Z, Cao Q Am J Transl Res. 2024; 16(11):6852-6866.

PMID: 39678621 PMC: 11645625. DOI: 10.62347/MCEE4840.

Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.

Song J, Li N, Zhuang Y, Chen Y, Zhang C, Zhu J Front Endocrinol (Lausanne). 2024; 15:1449558.

PMID: 39429734 PMC: 11486649. DOI: 10.3389/fendo.2024.1449558.

References

Diene G, Angulo M, Hale P, Jepsen C, Hofman P, Hokken-Koelega A . Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022; 108(1):4-12. PMC: 9759167. DOI: 10.1210/clinem/dgac549. View

Viner R, White B, Christie D . Type 2 diabetes in adolescents: a severe phenotype posing major clinical challenges and public health burden. Lancet. 2017; 389(10085):2252-2260. DOI: 10.1016/S0140-6736(17)31371-5. View

Holz 4th G, Leech C, Habener J . Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem. 1995; 270(30):17749-57. PMC: 3505614. View

Danne T, Biester T, Kapitzke K, Jacobsen S, Jacobsen L, Carlsson Petri K . Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. J Pediatr. 2016; 181:146-153.e3. DOI: 10.1016/j.jpeds.2016.10.076. View

Tamborlane W, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale P . Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019; 381(7):637-646. DOI: 10.1056/NEJMoa1903822. View

Lin L, Chu H, Murad M, Hong C, Qu Z, Cole S . Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med. 2018; 33(8):1260-1267. PMC: 6082203. DOI: 10.1007/s11606-018-4425-7. View

Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H . Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003; 144(12):5149-58. DOI: 10.1210/en.2003-0323. View

Mastrandrea L, Witten L, Carlsson Petri K, Hale P, Hedman H, Riesenberg R . Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatr Obes. 2019; 14(5):e12495. PMC: 6590663. DOI: 10.1111/ijpo.12495. View

Ding X, Saxena N, Lin S, Gupta N, Gupta N, Anania F . Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2005; 43(1):173-81. PMC: 2925424. DOI: 10.1002/hep.21006. View

10.

Klein D, Battelino T, Chatterjee D, Jacobsen L, Hale P, Arslanian S . Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014; 16(10):679-87. PMC: 4183917. DOI: 10.1089/dia.2013.0366. View

11.

Ryan P, Seltzer S, Hayward N, Rodriguez D, Sless R, Hawkes C . Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. J Pediatr. 2021; 236:137-147.e13. DOI: 10.1016/j.jpeds.2021.05.009. View

12.

Tamborlane W, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez E . Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care. 2022; 45(8):1833-1840. PMC: 9346995. DOI: 10.2337/dc21-2275. View

13.

Singhal S, Kumar S . Current Perspectives on Management of Type 2 Diabetes in Youth. Children (Basel). 2021; 8(1). PMC: 7826614. DOI: 10.3390/children8010037. View

14.

Thota P, Perez-Lopez F, Benites-Zapata V, Pasupuleti V, Hernandez A . Obesity-related insulin resistance in adolescents: a systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2017; 33(3):179-184. DOI: 10.1080/09513590.2016.1273897. View

15.

Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan D, Varela L, Haynes W . Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009; 29(18):5916-25. PMC: 6665241. DOI: 10.1523/JNEUROSCI.5977-08.2009. View

16.

Kelly A, Arslanian S, Hesse D, Iversen A, Korner A, Schmidt S . Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity (Silver Spring). 2023; 31(8):2139-2149. DOI: 10.1002/oby.23808. View

17.

Dickson K, Yeung C . PRISMA 2020 updated guideline. Br Dent J. 2022; 232(11):760-761. DOI: 10.1038/s41415-022-4359-7. View

18.

Valverde I, Morales M, Clemente F, Delgado E, Perea A, Villanueva-Penacarrillo M . Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. 1994; 349(2):313-6. DOI: 10.1016/0014-5793(94)00699-7. View

19.

Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen O . Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; 387(24):2245-2257. PMC: 9997064. DOI: 10.1056/NEJMoa2208601. View

20.

Weghuber D, Forslund A, Ahlstrom H, Alderborn A, Bergstrom K, Brunner S . A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. Pediatr Obes. 2020; 15(7):e12624. DOI: 10.1111/ijpo.12624. View